Streptozotocin-induced diabetes in rat. III. Antioxidant protection of vascular complications by flunarizine and aligeron.
In rats with streptozotocin-induced diabetes antioxidant protection of diabetic angiopathy was performed by flunarizine (10 mg/kg/day) and aligeron (10 mg/kg/day), applied intraperitoneally during 2.5 months of diabetes. Diabetic vascular complications were assessed by morphologic determination of PAS-positive mucopolysaccharides and measurement of vascular wall thickness in addition to quantitative estimation of lipid hydroperoxides, thromboxane A2/prostacyclin disbalance and plasma beta-thromboglobulin changes. Both drugs prevented development of diabetic angiopathy in rats by inhibition of lipid peroxidation, prostanoid synthesis and platelet activity, but the effect of flunarizine was more pronounced, which could be explained by its additional blocking effect of abnormal calcium flux into vascular cells. The free radical scavenging action of flunarizine and aligeron was investigated.
Somova
L
L
Institute of Endocrinology and Gerontology, Bulgarian Medical Academy, Sofia.
Dashev
G
G
Kirilov
G
G
Nikolov
R
R
Doncheva
M
M
Vassileva
M
M
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D002936:Cinnarizine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000473:pathology / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000473:pathology / Q000517:prevention & control*; D005444:Flunarizine / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D008054:Lipid Peroxides / Q000097:blood; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D014665:Vasodilator Agents / Q000627:therapeutic use*; D001620:beta-Thromboglobulin / Q000378:metabolism
D000975:Antioxidants; D008054:Lipid Peroxides; D014665:Vasodilator Agents; D001620:beta-Thromboglobulin; D002936:Cinnarizine; C021591:Aligeron; D005444:Flunarizine